Treatments for chronic inflammatory bowel diseases (IBDs) have considerably evolved over the last two decades. Advances in treatment have led to greater in-depth control of the diseases, in particular by achieving healing of lesions. Therapeutic objectives now include mucosal healing, essential for preventing complications and surgery. Early and intensive strategies, such as “Top-Down”, are showing increased efficacy in Crohn's disease. In 2024, new drugs such as mirikizumab and etrasimod offer new treatment options for ulcerative colitis. Particular attention is paid to fecal calprotectin, which plays a key role in IBD monitoring. It has become an indispensable tool for assessing inflammation and response to treatment, as well as predicting relapse. Our primary goal remains to improve the quality of life of IBD patients, but also to attempt to modify the natural history of these diseases through optimized monitoring and management.
Keywords
IBD, Crohn’s disease, ulcerative colitis, treatment calprotectin